ALK and neoplasm: While not specifically linked to ALK amplification, PCB-209 showed moderate sensitivity to crizotinib in vitro (Supplemental Table 3); thus, the ALK-inhibitor crizotinib was selected for in vivo PDX validation, which showed no statistically significant slowing of tumor growth versus control (p=0.5, Figure 4(a)).